Yahoo May Look to A...
Health Care: Drugs
Repros Therapeutics Inc. (RPRX: NASDAQ)
$16.69 -0.32 | -1.88%
05/17/13 - 04:00 PM ET
Ratio Comparisons
| Company | Industry | S&P 500 | |
| Valuation Ratios | |||
|---|---|---|---|
| P/E Ratio (TTM) | n.a. | 125.30 | 17.70 |
| P/E High - Last 5 Yrs | n.a. | n.a. | 67.70 |
| P/E Low - Last 5 Yrs | n.a. | n.a. | 12.50 |
| Beta | 0.18 | 0.63 | 0.98 |
| Price to Sales (TTM) | 103,722.71 | 7.02 | 1.42 |
| Price to Book (MRQ) | 19.10 | 6.47 | 2.41 |
| Price to Tangible Book (MRQ) | 22.28 | 14.29 | 5.08 |
| Price to Cash Flow (TTM) | -13.60 | 41.70 | 9.80 |
| Price to Free Cash Flow (TTM) | -17.20 | 139.40 | 17.40 |
| Dividends | |||
| Dividend Yield (%) | 0.00 | 0.40 | 2.10 |
| Dividend Yield - 5 Yr Avg (%) | n.a. | 0.20 | 2.30 |
| Dividend 5 Yr Growth Rate (%) | n.a. | 5.57 | 2.80 |
| Payout Ratio (TTM) | 0.00 | 34.00 | 37.00 |
| Sales (MRQ) vs Qtr 1 Yr Ago (%) | n.a. | 25.00 | 0.30 |
| Sales (TTM) vs TTM 1 Yr Ago (%) | 50.00 | 35.70 | 2.20 |
| Growth Rates (%) | |||
| Sales - 5 Yr Growth Rate (%) | n.a. | 11.34 | 3.62 |
| EPS (MRQ) vs Qtr 1 Yr Ago (%) | n.a. | 17.70 | 99.90 |
| EPS (TTM) vs TTM 1 Yr Ago (%) | n.a. | 17.70 | 99.90 |
| EPS - 5 Yr Growth Rate (%) | n.a. | n.a. | 8.12 |
| Capital Spending - 5 Yr Growth Rate (%) | -30.78 | 14.10 | 3.83 |
| Financial Strength | |||
| Quick Ratio (MRQ) | 4.70 | 2.60 | 1.10 |
| Current Ratio (MRQ) | 4.80 | 3.40 | 1.60 |
| LT Debt to Equity (MRQ) | 0.00 | 0.64 | 0.73 |
| Total Debt to Equity (MRQ) | 0.00 | 0.69 | 0.86 |
| Interest Coverage (TTM) | n.a. | 4.60 | 6.70 |
| Profitability Ratios (%) | |||
| Gross Margin (TTM) | n.a. | 80.70 | 47.80 |
| Gross Margin - 5 Yr Avg | n.a. | 82.90 | 47.00 |
| EBITD Margin (TTM) | n.a. | 22.00 | 19.50 |
| EBITD - 5 Yr Avg | -1,547.67 | 0.00 | 0.00 |
| Pre-Tax Margin (TTM) | n.a. | 11.60 | 11.70 |
| Pre-Tax Margin - 5 Yr Avg | n.a. | 13.40 | 10.20 |
| Management Effectiveness (%) | |||
| Net Profit Margin (TTM) | 0.00 | 0.08 | 0.09 |
| Net Profit Margin - 5 Yr Avg | n.a. | 7.40 | 6.30 |
| Return on Assets (TTM) | -116.00 | 4.20 | 3.20 |
| Return on Assets - 5 Yr Avg | -139.00 | 3.10 | 2.30 |
| Return on Investment (TTM) | -141.00 | 5.40 | 8.50 |
| Return on Investment - 5 Yr Avg | -186.00 | 4.10 | 5.90 |
| Efficiency | |||
| Revenue/Employee (TTM) | 143.00 | n.a. | n.a. |
| Net Income/Employee (TTM) | -110,004.00 | n.a. | n.a. |
| Receivable Turnover (TTM) | n.a. | 6.00 | 7.90 |
| Inventory Turnover (TTM) | n.a. | 1.80 | 7.70 |
| Asset Turnover (TTM) | 0.00 | 0.50 | 0.40 |
Portfolios with RPRX
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ContributorEarnings Short Squeeze Play...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks With Big Insider Buy...
- ContributorStocks Under-$10 Moving Hig...
- Contributor10 Cheap Biotech Stocks Tha...
- Contributor16 Small-Cap Stocks in Dang...
- ContributorUnder $5 Stocks at Risk of ...
- UserSUPRATRADE Top Day Trader A...
- UserMicrobanks
Latest RPRX Headlines from TheStreet
- Repros Reports Issuance Of Two Additional U.S. Androxal(R) Patents 04.10.13 | 12:04 pm
- The Five Dumbest Things on Wall Street: April 5
04.05.13 | 06:04 am - Repros CEO: My Testosterone Drug Helped Gay Cubans Have Lots of Sex 03.28.13 | 12:03 pm
- Repros Reports Both Primary Endpoints Successfully Met In First Pivotal Study Of Androxal(R) 03.27.13 | 08:03 pm
- American Urological Association (AUA) Accepts Androxal(R) Versus Topical Gel Comparative Study For Podium Presentation At Annual Meeting 03.25.13 | 10:03 am
- Repros Therapeutics Inc.(R) Reports Fourth Quarter And Year End 2012 Financial Results 03.18.13 | 09:03 am
- FDA Grants Repros An End Of Phase 2 Meeting In Late May To Discuss Proellex(R)-V Phase 3 Study Design 02.28.13 | 09:02 am
- Repros Reports FDA Recommends Pivotal Study ZA-301 Of Androxal(R) To Be Completed As Originally Planned 02.21.13 | 07:02 am
- Repros Therapeutics Corporate Update 02.11.13 | 09:02 am
- Repros Updates Guidance For Top Line Results From First Pivotal Androxal(R) Study To Q3 2013 01.28.13 | 06:01 am
Press Releases for RPRX
- Repros® Announces Dismissal Of Class Action Lawsuits - Business Wire 03.03.11 | 05:03 pm
- Repros Therapeutics® Announces Pricing Of Public Offering Of Common Stock And Warrants - Business Wire 02.03.11 | 03:02 pm
- Repros Therapeutics® Receives IRB Approval To Commence Phase IIb Study Of Androxal® In The Treatment Of Secondary Hypogonadism - Business Wire 01.03.11 | 09:01 am
- Reanalysis By Outside Statistician Shows Androxal® Provides Statistically Significant Improvement In Testosterone Levels In Men With Male Hormone Levels ≤ 250 Ng/dL - Business Wire 12.28.10 | 09:12 am
- Vaginal Delivery Of Repros’® Proellex® Bypasses First Pass Liver Effects And Achieves Greater Signals Of Efficacy At Significantly Lower Exposure - Business Wire 12.27.10 | 09:12 am
- Repros® Therapeutics Submits Data To The FDA Supporting Morning Assessment Of Testosterone For Men Treated With Androxal® As Indicative Of Average And Maximum Levels Attained - Business Wire 12.23.10 | 11:12 am
- Repros® Therapeutics Prepares To Commence Dosing In Second Cohort In Low Dose Proellex® Study - Business Wire 12.16.10 | 12:12 pm
- Repros Therapeutics Inc.® Reports Third Quarter 2010 Financial Results And Provides Corporate Update - Business Wire 11.10.10 | 06:11 am
- Repros® Announces Reverse Stock Split Effective On Nasdaq October 15, 2010 - Business Wire 10.14.10 | 08:10 pm
- FDA Grants Type B Meeting To Be Held November 8, 2010 To Discuss Phase III Protocols For Androxal® - Business Wire 09.30.10 | 06:09 am
Partner Headlines for RPRX
- Analysts: BlackBerry Rates Were Unimpressive and 4 New Opinions Investors Must Read Now - Wall St. Cheat Sheet 04.01.13 | 11:04 am
- Analysts: BlackBerry Rates Were Unimpressive and 4 New Opinions Investors Must Read Now - Wall St. Cheat Sheet 04.01.13 | 11:04 am
- Insiders Love These 3 Highly Shorted Healthcare Stocks - Seeking Alpha 01.23.13 | 09:01 am
- A Pullback Would Be Healthy For Repros Therapeutics - Seeking Alpha 09.20.12 | 09:09 am
- Update on Repros' Androxal - Analyst Blog - NASDAQ 09.14.12 | 09:09 pm
- Update on Repros' Androxal - Analyst Blog - Zacks 09.14.12 | 06:09 pm
- Earnings Miss at Repros - Analyst Blog - NASDAQ 08.17.12 | 06:08 pm
- A Closer Look At Repros Therapeutics - Seeking Alpha 07.29.12 | 07:07 am
- Four Biotechs to Watch Early This Week - Seeking Alpha 03.06.11 | 08:03 am
- UPDATE 1-Repros submits more testosterone drug data, shrs soar - Reuters 12.23.10 | 01:12 pm
